TACSTD2 and prostate cancer: As a class of drugs specifically targeted to tumors, TROP2-targeted therapeutics are widely regarded as poised to transform the future of solid tumor therapy, such as gastric cancer, pancreatic cancer, breast cancer, prostate cancer (58–61).